期刊文献+

高密度脂蛋白组分:心血管疾病诊治的新靶点 被引量:2

High-density Lipoprotein Compositions:New Targets for Diagnosis and Therapy in Cardiovascular Disease
下载PDF
导出
摘要 血浆高密度脂蛋白是由载脂蛋白、脂质及多种功能蛋白质共同组成的复合物。它可通过促进胆固醇逆转运、抗氧化、抗炎症反应及血管内皮保护等作用抑制动脉粥样硬化。高密度脂蛋白生理功能的发挥依赖于其组成成分和水平的正常。疾病时,高密度脂蛋白组分的异常修饰,或其含量及活性的变化均可导致其上述功能的改变,甚至使之转变成为促动脉粥样硬化性物质。因此,探明对高密度脂蛋白功能起关键作用的组分及疾病特异性组分变化可为心血管疾病的诊断和治疗提供新的靶点。 Composed of apolipoproteins, lipids and functional proteins, high-density lipoprotein( HDL) protects against atherosclero-sis with its ability to reverse cholesterol transport promotion, anti-oxidation and anti-inflammation, and direct endothelium protection.The physiological function of HDL depends on its normal compositions and levels.Modifications of HDL compositions and changes in their levels and activities can both contribute to its functional transformation towards pro-atherosclerosis.Therefore, finding the key components in HDL associated with its function and the specific changes during disease will provide new targets for the diagnosis and treatment in cardiovascular disease.
出处 《心血管病学进展》 CAS 2015年第3期233-237,共5页 Advances in Cardiovascular Diseases
基金 "重大新药创制"科技重大专项--<心血管创新药物临床研究技术平台建设>(2012ZX09303-008-001) 国家临床重点专科建设项目--<卫生部重点实验室项目>
关键词 高密度脂蛋白 动脉粥样硬化 胆固醇逆转运 脂质氧化 蛋白质组学 high-density lipoprotein atherosclerosis reverse cholesterol transport oxidation proteome
  • 相关文献

参考文献38

  • 1Acharjee S, Boden WE, Hartigan PM, et ah Low levels of high-density lipo- protein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients : a post-hoc analysis from the courage trial ( clinical out- comes utilizing revascularization and aggressive drug evaluation) [J]. J A1n Coil Cardiol, 2013,62(20) :1826-1833.
  • 2Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012,367(22) :2089- 2099.
  • 3Voight BF, Peloso GM, Orho-Melander M, et at. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study [ J]. Lancet, 2012,380(9841 ) :572-580.
  • 4Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and ather- opreteetlon: ad'ancing the concept of reverse cholesterol transport[J]. Circula- tion, 2012,125(15) :1905-1919.
  • 5Davidson WS, Silva RA, Chantepie S, et ah Proteomic analysis of defined HDL suhpopulations reveals particle-specific protein clusters: relevance to an- tioxidative function [ J ]. Arterioscler Thromb Vase Biol, 2009,29 ( 6 ) : 870- 876.
  • 6Zerrad-Saad.i A, Therond P, Chamepie S, et ai. HDL3-mediated inactivation of LDL-associated phospholipid hydroperexides is determined by the redox status of apolipopretein A-I and HDL particle surface lipid rigidity: relevance to inflam- mation and atherogenesis[ J]. Arterioscler Thromb Vasc Biol, 2009,29 (12) : 2169-2175.
  • 7Rosenson RS, Brewer HB Jr, Ansell B, et ah Translation of high-density lipo-protein function into clinical practice: current prospects and future challenges [ J ]. Circulation, 2013,128 ( 11 ) : 1256 -1267.
  • 8Zhang QH, Zu XY, Cao RX, et al. An involvement of SR-B1 mediated PI3K- AKT-eNOS signaling in HDL-induced cyclooxygenase 2 expression and prostacy- elin production in endothelial cells[ J]. Biochem Biophys Res Commun, 2012, 420(1) :17-23.
  • 9Wilkerson BA, Grass GD, Wing SB, et al. Sphingosine 1 -phosphate ( S1 P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-SIP prolongs endothe|ial barrier enhancement as compared with albu- min-SIP via effects on levels, trafficking, and signaling of S1PI [ J]. J Biol Chem, 2012,287 ( 53 ) :44645-44653.
  • 10Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease [J]. J Clin Invest, 2011,121(7) :2693-2708.

同被引文献13

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部